您的位置: 首页 > 2019年3月 第50卷 第2期 > 文字全文
2023年7月 第38卷 第7期11
目录

ABCB1基因G2677T、C3435T多态性与阿托伐他汀降脂疗效的关系

Correlation between ABCB1 gene G2677T, C3435T polymorphism and atorvastatin lipidlowering efficacy

来源期刊: 广州医药 | 63-68 发布时间:2021-12-17 收稿时间:2025/11/13 17:34:40 阅读量:33
作者:
关键词:
阿托伐他汀ABCB1基因多态性降脂疗效
DOI:
10.3969/j.issn.1000-8535.2019.02.016
收稿时间:
2018-11-01 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 分析ABCB1基因G2677T、C3435T位点在我国汉族血脂异常人群的分布特征;探讨ABCB1基因G2677T和C3435T多态性与阿托伐他汀降脂疗效之间的关系。方法 依据中国成人血脂异常防治指南判断标准,在中国汉族人群中收集205例受试者,抽取其外周血液样本,利用聚合酶链式反应-限制性片段长度多态分析(PCR-RFLP)技术对受试者ABCB1进行基因分型,同时在阿托伐他汀治疗3个月前后检测总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)血脂水平,将205例患者治疗后4项指标恢复正常分为A组,治疗后4项指标仍有一项及一项以上异常分为B组,来分析G2677T和C3435T基因多态性与阿托伐他汀降脂疗效的关系,以及G2677T和C3435T等位基因的分布特征。结果 205例患者中G2677T位点GG型、GT型、TT型基因频率分别为19.51%、42.44%、38.05%;C3435T位点CC型、CT型、TT型基因频率分别为34.63%、49.76%、15.61%。G2677T位点A组与B组等位基因突变率为58.46%与60.67%,A组GG型、GT型、TT型基因频率分别为23.08%、36.92%、40.00%,B组GG型、GT型、TT型基因频率分别为13.33%、52.00%、34.67%;C3435T位点A组与B组等位基因突变率为40.77%和40.00%,A组CC型、CT型、TT型基因频率分别为34.62%、 49.23%、16.15%,B组CC型、CT型、TT型基因频率分别为34.67%、50.67%、14.66%;ABCB1 基因G2677T、C3435T位点基因型在A组和B组中分布相同,无差异(P>0.05)。205例患者中,用药前ABCB1基因G2677T位点TT型血浆TC、LDL-C水平高于GT型(P<0.05)。用药后ABCB1基因G2677T位点GT型血浆TC、HDL-C、LDL-C水平低于GG型与TT型(P<0.05);用药后ABCB1基因C3435T位点TT型血浆TC水平低于CC与CT型(P<0.05),而CC型血浆LDL-C水平高于TT型(P<0.05)。结论 ABCB1基因G2677T、C3435T位点多态性与血浆血脂水平有关,但ABCB1基因G2677T、C3435T位点多态性可能与阿托伐他汀3个月降脂疗效无关。
1、 国家卫生计生委合理用药专家委员会. 冠心病合理用药指南[J]. 中国医学前沿杂志,2016,8(6):19-108. 国家卫生计生委合理用药专家委员会. 冠心病合理用药指南[J]. 中国医学前沿杂志,2016,8(6):19-108.
2、 姚震,陈林. 我国心血管疾病现状与展望[J]. 海南医学,2013,24(13):1873-1876. 姚震,陈林. 我国心血管疾病现状与展望[J]. 海南医学,2013,24(13):1873-1876.
3、 易德青. 血脂异常的危险因素及脂代谢关联基因相关性研究[D]. 汕头大学,2011. 易德青. 血脂异常的危险因素及脂代谢关联基因相关性研究[D]. 汕头大学,2011.
4、 郑炜平,陈海峰.阿托伐他汀对高血压合并高低密度脂蛋白胆固醇血症患者肾功能的影响[J]. 中华高血压杂志,2016,24(1):56-60. 郑炜平,陈海峰.阿托伐他汀对高血压合并高低密度脂蛋白胆固醇血症患者肾功能的影响[J]. 中华高血压杂志,2016,24(1):56-60.
5、 郑雅俊.ABCB1、ABCA1基因SNPs与阿托伐他汀调脂疗效的关系[D]. 皖南医学院,2014. 郑雅俊.ABCB1、ABCA1基因SNPs与阿托伐他汀调脂疗效的关系[D]. 皖南医学院,2014.
6、 HAN S H, KANG E W, YOON S J, et al. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis [J]. Nephrol Dial Transplant,2011, 26(11): 3722-3728. HAN S H, KANG E W, YOON S J, et al. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis [J]. Nephrol Dial Transplant,2011, 26(11): 3722-3728.
7、 PRADO Y,SAAVEDRA N,ZAMBRANO T,et al. Slco1b1c. 388a>g polymorphism is associated with hdlc levels in response to atorvastatin in chilean individuals[J]. Int J Mol Sci,2015,16(9):20609-20619. PRADO Y,SAAVEDRA N,ZAMBRANO T,et al. Slco1b1c. 388a>g polymorphism is associated with hdlc levels in response to atorvastatin in chilean individuals[J]. Int J Mol Sci,2015,16(9):20609-20619.
8、 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35:390-418. 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35:390-418.
9、 HAO F F, DU Y M, LAI Y. Advance in search for gene polymorphisms on pharmacokinetics of atorvastatin [J]. Chin J New Drug Clin Rem, 2012, 31(3): 128-133. HAO F F, DU Y M, LAI Y. Advance in search for gene polymorphisms on pharmacokinetics of atorvastatin [J]. Chin J New Drug Clin Rem, 2012, 31(3): 128-133.
10、 LOSCHER W,KLOTZ U,ZIMPRICH F,et al. The clinical impact of pharmacogenetics on the treatment of epilepsy[J]. Epilepsia,2009,50(1):1-23. LOSCHER W,KLOTZ U,ZIMPRICH F,et al. The clinical impact of pharmacogenetics on the treatment of epilepsy[J]. Epilepsia,2009,50(1):1-23.
11、 ZINTZARAS E. Is there evdience to claim or deny association between variants of the multidrug resistance gene(MDR1 or ABCB1)and inflammatory bowel disease[J]. Inflamm Bowel Dis,2012,18(3):562-572. ZINTZARAS E. Is there evdience to claim or deny association between variants of the multidrug resistance gene(MDR1 or ABCB1)and inflammatory bowel disease[J]. Inflamm Bowel Dis,2012,18(3):562-572.
12、 WU H,KANG H,LIU Y,et al. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes[J]. J Cancer Res Clin Oncol,2012,138(9):1449-1462. WU H,KANG H,LIU Y,et al. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes[J]. J Cancer Res Clin Oncol,2012,138(9):1449-1462.
13、 HAMIDOVIC A,HAHN K,KOLESAR J. Clinical significance of ABCB1 genotyping in oncology[J]. J Oncol Pharm Pract,2010,16(1):39-44. HAMIDOVIC A,HAHN K,KOLESAR J. Clinical significance of ABCB1 genotyping in oncology[J]. J Oncol Pharm Pract,2010,16(1):39-44.
14、 KIM H J,HWANG S Y,KIM I H,et al. Association between genetic polymorphism of multidrug resistance 1 gene and sasang constitutions[J]. Evid Based Complement Altemat Med,2009,66(1):73-80. KIM H J,HWANG S Y,KIM I H,et al. Association between genetic polymorphism of multidrug resistance 1 gene and sasang constitutions[J]. Evid Based Complement Altemat Med,2009,66(1):73-80.
15、 KAJINAMI K,BROUSSEAU M E,ORDOVAS J M,et al. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a genderspecific manner[J].Am J Cardiol,2004, 93: 1046-1050. KAJINAMI K,BROUSSEAU M E,ORDOVAS J M,et al. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a genderspecific manner[J].Am J Cardiol,2004, 93: 1046-1050.
16、 YUAN Z, LI X H, HUANG S B, et al. The molecular mechanism of actin of OATP1B1 and CYP3A4 genetic polymorphism on the metabolism and transport of atorvastatin [J]. Chin Hosp Pharm J, 2013, 33(13): 1035-1041. YUAN Z, LI X H, HUANG S B, et al. The molecular mechanism of actin of OATP1B1 and CYP3A4 genetic polymorphism on the metabolism and transport of atorvastatin [J]. Chin Hosp Pharm J, 2013, 33(13): 1035-1041.
17、 HE A X, SHI L, ZHAO J S.Advances in search for pharmacogenomics of atorvastatin[J]. Chin J Clin Pharmacol,2011,27(11):888-891. HE A X, SHI L, ZHAO J S.Advances in search for pharmacogenomics of atorvastatin[J]. Chin J Clin Pharmacol,2011,27(11):888-891.
18、 BANDDUR S, PETRASEK J, HRIBOVA P, et al. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients[J]. Transplantation,2008,86(9):1206-1213. BANDDUR S, PETRASEK J, HRIBOVA P, et al. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients[J]. Transplantation,2008,86(9):1206-1213.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录